Current treatment of choice for chronic hepatitis C infection

Research output: Contribution to journalReview articlepeer-review

9 Scopus citations


More than three million Americans have chronic hepatitis C infection, and the disease remains one of the most common blood-borne infections in the US. Treatment is focused on the chronic form of the disease, because the acute one tends to be self-limiting. In this article, we review the recent literature regarding the most effective therapy against hepatitis C infection, to confirm the current treatment of choice for the disease. We conclude that combination therapy with pegylated interferon and ribavirin remains the initial treatment of choice. New research focusing on adjuvant therapies, such as protease and polymerase inhibitors, has yielded early data that appear to be promising.

Original languageEnglish (US)
Pages (from-to)11-18
Number of pages8
JournalInfection and Drug Resistance
Issue number1
StatePublished - 2011

All Science Journal Classification (ASJC) codes

  • Pharmacology
  • Infectious Diseases
  • Pharmacology (medical)


Dive into the research topics of 'Current treatment of choice for chronic hepatitis C infection'. Together they form a unique fingerprint.

Cite this